Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute

Reuters11-03
Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute

Nautilus Biotechnology Inc. has announced the successful installation and testing of its first external field evaluation unit at the Buck Institute for Research on Aging. Over six months, researchers at the Buck Institute used Nautilus' next-generation single-molecule proteomics platform to generate highly reproducible data from neurodegenerative disease samples, including novel insights into tau proteoforms. These results validate the platform's robust performance and its potential to advance understanding of aging and neurodegeneration, such as Alzheimer's disease. The scientific findings from this collaboration will be presented at the 2025 HUPO World Congress seminar, "Redefining Proteomics with Single-Molecule Iterative Mapping," scheduled for November 10, 2025, in Toronto.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566730-en) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment